Andy Vicari: March 17, 2020


Lower-priced insulins and other options for people with diabetes who need help affording their Lilly insulin


Andy Vicari

Senior Director & U.S. Brand Leader, Insulins, Eli Lilly and Company



Millions of Americans with high-deductible insurance plans are facing high out-of-pocket costs because their plans reset at the beginning of the year. Individuals on these plans are sometimes forced to make tough decisions when it comes to their health. Eli Lilly and Company is committed to helping those who face higher out-of-pocket costs afford their Lilly insulin. This is why Lilly offers insulin options with lower list prices and additional resources through the Lilly Diabetes Solution Center.


Launched in 2018, the Lilly Diabetes Solution Center is available to people who need help affording their Lilly insulin. The Lilly Diabetes Solution Center is staffed by health care professionals and may provide significant savings on Lilly insulins in multiple ways, including out-of-pocket caps on what people with commercial insurance pay at the pharmacy and information about how to access donated Lilly insulin at more than 150 free clinics in the U.S. Anyone who needs help affording their Lilly insulin should can the Lilly Diabetes Solution Center at 833-808-1234, Monday-Friday 9 a.m. to 8 p.m.


Did you know?

  • The percentage of workers covered by healthcare plans that require an annual deductible has jumped from 55 percent in 2006 to 81 percent in 2015.[i] These high-deductible plans mean higher out-of-pocket costs for people until they reach the deductible.
  • The cost of treating diabetes for some of the 30 million Americans with the condition[ii] has increased over the past several years, including how much they pay for their medicines.
  • Lilly’s insulin affordability options are helping up to 20,000 people each month meaningfully lower the amount they pay for their Lilly insulin at the pharmacy.
  • Lilly’s first lower-priced insulin, Insulin Lispro Injection (100 units/mL), was launched in May 2019 at a 50 percent lower list price than the branded version, Humalog (insulin lispro injection, 100 units/mL).
  • In <December 2019>, people filled more than <79,000> prescriptions for Insulin Lispro Injection, which now makes up approximately <11%> of the Humalog family prescriptions.
  • In April 2020 Lilly is expanding its suite of affordability options to include lower-priced versions of Humalog® Mix75/25™ KwikPen® (insulin lispro protamine and insulin lispro injectable suspension 100 units/mL) and Humalog® Junior KwikPen® (insulin lispro injection 100 units/mL). Each will be available for a 50 percent lower list price than the branded counterparts.


On March 5th, Andy Vicari is available to you and your listeners to talk about how people who use Lilly insulin can identify affordability solutions.


For more information please visit www.insulinaffordabilitycom 



Andy Vicari is Senior Director & U.S. Brand Leader for the Insulins portfolio at Eli Lilly and Company. In this role, Andy leads the brand teams in developing and executing cross-portfolio marketing strategies across various insulin brands at Lilly. Andy has held several leadership positions in sales and marketing. Outside of work, Andy serves on the Board of Directors for the American Diabetes Association. He earned a bachelor’s degree in Biomedical Sciences from St. Cloud State University and a Master of Business Administration from the University of Illinois at Urbana-Champaign.


Speak Your Mind